Home » Stocks » ProQR Therapeutics

ProQR Therapeutics N.V. (PRQR)

Stock Price: $5.32 USD -0.35 (-6.17%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed
After-hours: $5.35 +0.03 (0.56%) Aug 12, 5:55 PM

Stock Price Chart

Key Info

Market Cap 287.15M
Revenue (ttm) 2.28M
Net Income (ttm) -66.87M
Shares Out 50.14M
EPS (ttm) -1.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $5.32
Previous Close $5.67
Change ($) -0.35
Change (%) -6.17%
Day's Open 5.80
Day's Range 5.06 - 5.80
Day's Volume 211,418
52-Week Range 4.46 - 10.98

More Stats

Market Cap 287.15M
Enterprise Value 171.21M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 50.14M
Float 37.10M
EPS (basic) n/a
EPS (diluted) -1.31
FCF / Share -1.30
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 628,513
Short Ratio 4.06
Short % of Float 1.67%
Beta 0.52
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 126.06
PB Ratio 2.72
Revenue 2.28M
Operating Income -67.69M
Net Income -66.87M
Free Cash Flow -53.23M
Net Cash 115.94M
Net Cash / Share 2.14
Gross Margin 100.00%
Operating Margin -2,971.81%
Profit Margin -2,935.60%
FCF Margin -2,336.83%
ROA -34.50%
ROE -68.04%
ROIC n/a
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(381.55% upside)
Current: $5.32
Target: 25.62
*Average 12-month USD price target from 8 stock analysts.

Financial Performance

Financial numbers in millions EUR.

Financial Overview

Revenue Growth-66.45%285.35%-18.22%-43.49%933.55%169.83%-
Gross Profit1.935.761.501.833.240.310.12
Operating Income-57.45-36.29-40.50-39.57-27.00-16.46-3.24
Net Income-56.75-37.09-43.68-39.10-20.83-12.13-3.25
Shares Outstanding41.0434.0525.3723.3523.3411.085.52
Earnings Per Share-1.38-1.08-1.72-1.67-0.89-1.09-0.59
Operating Cash Flow-44.59-28.62-35.10-34.22-24.23-14.46-2.33
Capital Expenditures-0.58-0.31-0.12-2.54-1.30-1.11-0.14
Free Cash Flow-45.17-28.93-35.22-36.76-25.53-15.57-2.47
Cash & Equivalents11210648.1059.2094.871134.13
Total Debt13.569.397.245.704.842.863.54
Net Cash / Debt98.3996.1940.8653.5090.031100.59
Book Value94.3392.9239.3653.1489.80109-0.09
Numbers in millions EUR, except per-share numbers.

Company Profile

Company Details

Full Name ProQR Therapeutics N.V.
Country Netherlands
Employees 154
CEO Daniel Anton de Boer

Stock Information

Ticker Symbol PRQR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PRQR
IPO Date September 18, 2014


ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase 1/2 stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase 1/2 aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with General Hospital Corporation, Radboud University Medical Center, Inserm Transfert SA, and Leiden University Medical Center. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.